Analyst DowngradeAnalyst downgrades RLMD from Neutral to Sell and lowers the 12-month price target to $2 from $3 due to increased risk associated with the Ph3 RELIANCE II trial.
Psychiatrist HesitationKey opinion leaders express hesitation to prescribe REL-1017, even if approved, due to lingering concerns over abuse potential.
Trial ExecutionPotential impact from the same trial execution missteps that led to the failure of the two prior Ph3 RELIANCE I and RELIANCE III trials is noted.